The overall response rate of this revolutionary cancer therapy named FUCASO is 96%. The NMPA’s approval marks a turning point in China’s fight against multiple myeloma. This blog explores the effectiveness of this therapy, its safety, and its potential to improve patient outcomes. Dive in and learn more about FUCASO and the hope it brings for refractory Multi myeloma marasa lafiya.
Multiple myeloma, ciwon daji na jini wanda ke shafar ƙwayoyin plasma, na iya zama abokin gaba mai ban tsoro. Yana rage rigakafi, kuma yana raunana kashi, kuma, duk da ci gaban da aka samu, har yanzu yana da wuya a sami magunguna na dogon lokaci. An kiyasta yawan myeloma zai shafi kusan mutane 176,404 a duk duniya a cikin 2020.
Multiple myeloma is the second most prevalent type of blood cancer, after linzoma, yet it is still considered rare. It is more common in elderly people, with the average age of diagnosis being about 70. But there’s a ray of hope with advanced CAR T tantanin halitta a kasar Sin.
Kwanan nan Hukumar Kula da Kayayyakin Magunguna ta kasar Sin (NMPA) ta amince da wani sabon BCMA CAR T maganin ciwon daji a kasar Sin wanda ake kira FUCASO, wanda ke nuna yiwuwar sauyin yanayi wajen yakar wannan cuta mai sarkakiya. Don haka, menene myeloma mai yawa, kuma me yasa FUCASO ke haifar da irin wannan farin ciki?
Nazarin baya-bayan nan ya nuna alƙawarin alƙawarin yayin gwaji, tare da ƙimar amsa gabaɗaya na 96% da cikakken ƙimar amsawa na 74.3% da aka lura a cikin 103 da aka yiwa rajista. Wannan shafin yanar gizon ya zurfafa zurfin ilimin kimiyya a bayan FUCASO, tasirin da zai iya tasiri ga marasa lafiya na myeloma, da kuma begen da yake kawowa ga yakin duniya na yaki da wannan cuta mai kalubale.
Shin tsadar tsadar da ke da alaƙa da maganin cutar kansa yana sa ku ji da mummunan tunani?
Babu buƙatar ƙarin damuwa! Kawai danna nan ka gano maganin kansar kyauta a kasar Sin wanda ke ba da sabon bege ga marasa lafiya a duk faɗin duniya.
Menene Cutar Myeloma Multiple?
Multiple myeloma, wanda aka fi sani da plasma cell myeloma ko kawai myeloma, ciwon daji ne na ƙwayoyin plasma, waɗanda fararen jini ne da ake samu a cikin kasusuwa. Kwayoyin Plasma gabaɗaya suna samar da ƙwayoyin rigakafi, waɗanda sune sunadaran da ke taimakawa jikin ku yaƙar cututtuka.
Kwayoyin Plasma a cikin myeloma da yawa suna haɓaka da rashin daidaituwa kuma suna ƙaruwa ba tare da kulawa ba. Waɗannan ƙwayoyin ƙwayoyin plasma marasa al'ada suna tattara ƙwayoyin jini masu lafiya a cikin kasusuwa, wanda ke haifar da samar da sunadaran M na rashin daidaituwa.
Gano Alamomin: Jagora Mai Fadakarwa Akan Alamomin Wasa da Alamomin Myeloma da yawa
Tasirin Multiple Myeloma A Jikin Dan Adam:
Lalacewar kashi: M sunadaran da ƙwayoyin plasma mara kyau na iya lalata nama na kasusuwa, haifar da ciwo, karaya, da osteoporosis.
Matsalolin koda: M sunadaran suna iya taruwa a cikin koda kuma suna lalata aikinsu.
Anemia: Cirewar ƙwayoyin jini masu lafiya ta ƙwayoyin plasma marasa kyau na iya haifar da anemia, haifar da gajiya da ƙarancin numfashi.
Raunin rigakafi: Kwayoyin plasma marasa al'ada ba su iya ƙirƙirar ƙwayoyin rigakafi na yau da kullun, suna sa jiki ya zama mai saurin kamuwa da cututtuka.
Karanta Wannan: Ta yaya Hoto Ganewa ke Ceto Rayuka a Yaƙin Myeloma da yawa?
Kimiyya Bayan Jiyya na FUCASO Don Multiple Myeloma A China
FUCASO (Equecabtagene Autoleucel) yana kama da maganin ciwon daji na ƙasa don hadadden ciwon daji da ake kira mahara myeloma, musamman ga mutanen da ciwon daji ya dawo bayan jiyya na baya (sake dawowa ko refractory multiple myeloma, RRMM).
Wannan magani na musamman yana amfani da ƙarfin tsarin garkuwar jikin mutum don yaƙar kansa ta hanyar keɓantacce kuma mai yuwuwar warkewa. A cikin wannan jiyya, ana canza ƙwayoyin T tare da masu karɓa na musamman da ake kira CARs (Chimeric Antigen Receptors), suna mai da su kamar makamai masu linzami masu shiryarwa waɗanda za su iya ganewa da kai hari kan takamaiman maƙasudi akan ƙwayoyin cutar kansa. Maganin FUCASO na myeloma da yawa a kasar Sin na musamman ne saboda wasu dalilai masu mahimmanci:
Cikakken-Dan Adam: Ba kamar wasu jiyya iri ɗaya ba, FUCASO yana amfani da kayan aikin ɗan adam gaba ɗaya, yana sa ya zama ƙasa da yuwuwar haifar da ƙin yarda da illa.
BCMA-Specific: CAR a cikin FUCASO na musamman yana hari BCMA, furotin da ke cikin ƙwayoyin myeloma. Wannan daidaito yana rage yawan lalacewa ga kyallen takarda masu lafiya.
Lentivirus As A Gene Vector: Wannan hanya ce mai inganci don isar da kwayoyin halitta zuwa ƙwayoyin T. Yana ba da damar T lymphocytes su gane da lalata ƙwayoyin myeloma.
Ƙarfi Kuma mai dagewa: FUCASO an gwada shi sosai kuma an gano cewa yana da tasiri sosai kuma yana dadewa a cikin marasa lafiya tare da myeloma mai yawa, yana ba da bege ga gafara na dogon lokaci.
Hukumar Kula da Kayayyakin Kiwon Lafiya ta kasar Sin (NMPA) kwanan nan ta ba da koren haske ga FUCASO® da za a yi amfani da shi wajen magance myeloma da yawa. Godiya ga ƙoƙarin Innovent Biologics da IASO Bio, ana samun wannan jiyya mai kama da jarumai a yanzu, wanda ke nuna babban ci gaba a yaƙi da wannan ƙalubalen cuta. Wannan sabon magani yana kawo sabon haske na bege ga kyakkyawar makoma mai haske.
Har ila yau karanta: Immunotherapy na iya Taimaka muku cin nasarar yaƙi da Myeloma da yawa!
Menene ya faru yayin gwajin Jiyya na FUCASO don Multiple Myeloma a China?
The FUMANBA-1 gwajin gwaji, conducted in China, examined the efficacy and safety of FUCASO (Equecabtagene Autoleucel) in patients with relapsed or refractory multiple myeloma (RRMM). The trial included 103 patients who each got a single dose of FUCASO, a CAR-T cell therapy for cancer in China.
Sakamakon wannan binciken na asibiti yana da ban sha'awa da gaske:
Babban amsawar amsawa: 96% na marasa lafiya sun amsa maganin, tare da 74.3% sun sami cikakkiyar amsa mai ƙarfi (sCR) ko cikakkiyar amsa (CR), wanda ke nufin babu ƙwayoyin cutar kansa da za a iya gane su.
Amsa da sauri: Matsakaicin lokacin amsawa shine kawai kwanaki 16, yana nuna tasiri mai sauri akan cutar.
Dorewa mai ɗorewa: A cikin watanni 12, 78.8% na marasa lafiya har yanzu ba su da ci gaba, yana nuna ingancin maganin na dogon lokaci.
Zurfafa remissions: 95% na marasa lafiya sun sami mafi ƙarancin cuta (MRD) mara kyau, wanda ke nufin akwai ƙananan ƙwayoyin cutar kansa da ba za a iya gano su ba.
Mai tasiri a cikin majinyatan da aka bi da su: Ko da marasa lafiya da suka sami kafin CAR-T far sun amsa da kyau, tare da 9 cimma CR da 5 cimma sCR.
Ingantaccen bayanin martaba na aminci: Mutane kaɗan ne kawai suka ci karo da ƙananan illa irin su ciwon sakin cytokine ko neurotoxicity, kuma duk sun murmure sosai.
Dagewar jiyya: A cikin watanni 12 da 24, an gano ƙwayoyin FUCASO a cikin yawancin marasa lafiya, suna nuna yiwuwar yin aiki mai dorewa.
Waɗannan bayanan, waɗanda aka gabatar a ƙungiyar American Society of Clinical Oncology taron a 2023, suna nuna alƙawarin FUCASO a matsayin babban nasara kuma ingantaccen jurewa maganin myeloma da yawa.
Menene Kudin Jiyya na FUCASO Don Multiple Myeloma A China?
Kudin jiyya na FUCASO na myeloma da yawa a China yana kusa da $160,000 USD. Duk da yake wannan yana iya zama babban adadin kuɗi, yana da mahimmanci a san cewa wannan jiyya wani muhimmin mataki ne na ci gaba wajen taimaka wa mutane da myeloma masu yawa.
Yana ba da dama don ingantattun sakamako da ingantacciyar rayuwa. Idan kuna la'akari da wannan maganin, yana da kyau ku tuntuɓi likitocin ku ko tuntuɓar mu don taimakon kuɗi idan ba za ku iya biyan kuɗin magani ba.
The money spent on this new CAR T cell far in China is not just about paying for the treatment – it’s an investment in a new and better way to fight against multiple myeloma.
Mafi kyawun Asibitoci Don Jiyya na FUCASO Don Multiple Myeloma A China
Bari mu taimake ka gano wasu mafi kyau asibitoci a kasar Sin da ke ba da magani na FUCASO don myeloma da yawa.
Asibitin Cancer na Jami'ar Peking
Asibitin ciwon daji na jami'ar Peking sanannen cibiya ce da ake yi wa kallon daya daga cikin mafi kyawun wuraren kula da cutar kansa na kasar Sin. Yana kan ƙarshen ƙirƙira na likitanci, koyaushe yana tura iyakokin bincike na kansa, ganewar asali, da jiyya.
Musamman ma, Asibitin Ciwon daji na Jami'ar Peking majagaba ne a cikin maganin ƙwayar cuta ta CAR T, yana ba da wannan zaɓin naɗaɗɗen magani ga marasa lafiya da ke fuskantar cututtukan daji iri-iri, gami da myeloma da yawa.
Don haka, idan kuna la'akari da CAR T cell far don mahara myeloma, wannan asibiti babu shakka cibiya ce mai daraja da ta cancanci bincika.
Asibitin Shanghai Changzheng
Asibitin Changzheng, wanda ke tsakiyar birnin Shanghai, wani misali ne mai haske na ƙwararrun likitanci, yana ba da manyan jiyya irin su CAR T tantanin halitta don cututtukan daji na jini iri-iri, gami da myeloma mai yawa.
Sashen Nazarin Jiyya na Asibitin Changzheng yana jagorantar shirin CAR T tantanin halitta, ta yin amfani da shekarunsa na gwaninta da kayan aiki na musamman don samar da shirye-shiryen jiyya na keɓaɓɓen.
Ƙungiyoyin da suka sadaukar da su na likitocin jini, likitocin oncologists, da ma'aikatan aikin jinya suna aiki tare don tabbatar da kowane majiyyaci ya sami mafi kyawun kulawa a duk lokacin tafiya na jiyya.
Asibitin Lu-Daopei
Dokta Lu Daopei, sanannen masanin ilimin jini, ya kafa asibitin Lu-Daopei, wanda ya kafa kansa a matsayin jagora a fannin maganin cututtukan jini da bincike a kasar Sin. Musamman ma, suna da ƙwarewa sosai tare da jiyya na ƙwayoyin CAR-T, suna ba da wannan madadin juyin juya hali ga marasa lafiya da ke yaƙar myeloma da yawa da sauran cututtukan daji.
They were the first in China to use CAR-T cells to treat B-cell m lymphoblastic cutar sankarar bargo (B-ALL) and have since performed over 300 successful CAR-T procedures for various blood cancers.
Asibitin Gobroad Boren na Beijing
Sashen nazarin ilmin jini na asibitin Gobroad Boren na Beijing ya kware wajen magance cututtukan jini tare da gogewar sama da shekaru talatin a fannin asibiti da dakin gwaje-gwaje.
Sashen yana ba da cikakkiyar sabis na bincike da magani don cututtuka irin su myeloma da yawa, cutar sankarar bargo, lymphoma, thalassaemia, matsalolin coagulation, da ciwace-ciwacen jini.
Idan ya zo ga zaɓuɓɓukan magani, suna ba da nau'ikan hanyoyin kwantar da hankali don ciwace-ciwacen jini, gami da: chemotherapy, immunotherapy, far da aka yi niyya, da radiotherapy.
Isar da Ciwon dajiFax Don Taimakon Mahimmancin Maganin Myeloma da yawa
Idan kai ko wanda kake ƙauna yana hulɗa da myeloma da yawa, CancerFax yana nan don taimakawa. Mu kamar abokin abokantaka ne akan hanyar ku don ingantacciyar lafiya.
CancerFax yana aiki tare da manyan asibitocin ciwon daji a duk faɗin duniya, gami da MD Anderson, Memorial Sloan Kettering, da Mayo Clinic, don taimakawa marasa lafiya da ke neman ra'ayi na biyu ko kulawa na musamman don samun damar yin amfani da jiyya na zamani.
A cikin shekaru goma da suka gabata, muna taimakon mutane daga kasashe sama da 8, kuma a shirye muke mu tallafa muku ma. Tuntuɓe mu a yau don bincika mafi kyawun zaɓin CAR T Cell a China kuma fara hanyar ku don jin daɗi.
